Advertisement
  • Reuters

    Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments

    Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Sales from Vertex's top-selling CF drug Trikafta, also sold as Kaftrio in some markets, rose more than 18% from a year earlier to $2.48 billion in the quarter, beating analysts' expectations of $2.38 billion.

  • Reuters

    US Social Security, Medicare finances get slight boost from stronger economy

    Trust funds supporting Social Security and Medicare benefits for U.S. seniors are showing some improvement due to stronger-than-forecast economic growth, productivity and immigration that is boosting revenue collections, according to trustees' reports released by the U.S. Treasury on Monday. The Medicare Hospital Insurance Trust Fund's reserves are now expected to be depleted in 2036, five years later than was expected in last year's report, Treasury said. Reserves for the combined Social Security trust funds are now projected to be depleted in 2035, one year later than reported last year.

  • Benzinga

    Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data

    On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. These data were featured at the 2024 American Urological Association (AUA) Annual Meeting. Results featured updated data from Cohort 1 (C1),